Premium
The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1‐positive breast cancer cells
Author(s) -
Tang Ping,
Li Li,
Zhou Yan,
Shen CongCong,
Kang YuHuan,
Yao YuQin,
Yi Cheng,
Gou LanTu,
Yang JinLiang
Publication year - 2014
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1002/bab.1187
Subject(s) - cd3 , cytotoxicity , bispecific antibody , antibody , flow cytometry , monoclonal antibody , in vitro , chemistry , breast cancer , cancer research , immune system , microbiology and biotechnology , immunology , biology , cancer , biochemistry , cd8 , genetics
Abstract Bispecific antibody (BsAb) has been proved to be a very effective antitumor approach because of its distinctive advantages of immune‐mediated cytotoxicity. To enhance the ability to recruit and activate T lymphocytes for tumor‐specific killing, we constructed and prepared a recombinant human single‐chain Fv bispecific antibody (BsAb), named VEGFR1/CD3 BsAb, targeting VEGFR1 and CD3. The VEGFR1/CD3 BsAb was expressed in CHO‐K1 cells and purified by Ni‐NTA affinity chromatography. The CD3 and VEGFR1‐binding activity of VEGFR1/CD3 BsAb was confirmed by flow cytometry. T lymphocyte activation and proliferation induced by VEGFR1/CD3 BsAb were also demonstrated in vitro . Notably, our VEGFR1/CD3 BsAb presented a powerful and specific killing effect against VEGFR1‐positive human breast cancer cell MDA‐MB‐231 and MDA‐MB‐435 through activating T lymphocyte at very low concentrations, indicating that it will be a valuable antibody drug for treatment of VEGFR1‐positive cancers in the future.